FINHUB Insights

LH · Q3 FY24 · Jul 1 – Sep 30, 2024

Labcorp Q3 FY24: where the revenue came from and where it went

Labcorp Q3 FY24: revenue $3.3B (+7% year over year). Net profit $0.2B. Largest cohort Diagnostics $2.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2024
Reported
Oct 29, 2024 10-Q
Sankey diagram of Labcorp's income statement for Q3 FY24: revenue of $3.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.3B +7% year over year
Gross profit$0.9B 28% margin
Operating profit$0.3B 8% margin
Net profit$0.2B 5% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY24 (period ends Sep 30, 2024).
ItemValueShare of revenueYear over year
Revenue 3.3 100% +7%
Diagnostics 2.6 79% +9%
Drug Development 0.7 21% +3%
Cost of revenue−2.473%
Gross profit0.928% margin+0pp
SG&A−0.617%+0pp
Other−0.12%+0pp
Operating profit0.38% margin−1pp
Net profit0.25%−1pp
Filing on EDGAR More quarters of LH

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters